MATAWAN, N.J., May 31, 2006 (BUSINESS WIRE) -- PacificHealth Laboratories (PHLI) , a leading nutrition technology company, announced today that it has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
Professor David Thompson, leader of the Group that is based at Hope Hospital, will direct the research grant. Professor Thompson is one of the leading experts in the world on the neurology of the gut and the impact of appetite regulatory peptides such as cholecystokinin (CCK) on food intake. Professor Thompson's current research focuses on how specific nutrients can stimulate CCK and other appetite regulatory peptides.
Dr. Robert Portman, President & CEO of PacificHealth Laboratories said, "This collaboration with Professor Thompson and his group at Manchester will have important and positive implications on both our weight loss and Type II diabetes research efforts. We have been working informally with Professor Thompson for almost two years. Studies conducted by his lab on our appetite suppressant technology have enabled us to enhance its effectiveness and provide the first clinical evidence that this technology may have enormous application in the management of patients with Type II diabetes."
Dr. Portman continued, "Using a sophisticated assay, Professor Thompson has shown that our appetite suppressant formulation, which will be introduced under the brand name SATIETRIM(R), has a significant impact on gastric emptying. By slowing gastric emptying, SATIETRIM may have enormous utility in Type II diabetics by reducing peak insulin and glucose levels normally seen following consumption of a meal."
Professor Thompson said, "The potential of activating appetite regulatory peptides represents an exciting approach to both weight control and management of Type II diabetes, which represent two of the major worldwide health problems today. Although there are major ongoing efforts on development of drugs to potentiate appetite regulatory peptides, the selective use of specific nutrients may represent a more effective and better long-term solution."
About PacificHealth Laboratories. Inc.:
PacificHealth Laboratories, Inc. (PHLI.OB), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI's principle areas of focus include weight loss, management of Type II diabetes and sports performance. To learn more, visit www.pacifichealthlabs.com.
About the University of Manchester:
The University of Manchester ( www.manchester.ac.uk) is the largest higher education institution in the UK, with 24 academic schools and over 36,000 students. Its Faculty of Medical & Human Sciences ( www.mhs.manchester.ac.uk) is one of the largest faculties of clinical and health sciences in Europe, with a research income of around GBP 51 million (almost a third of the University's total research income). The School of Medicine ( www.medicine.manchester.ac.uk) is the largest of the Faculty's five Schools, with 1,300 staff and almost 2,000 undergraduates. The School encompasses five teaching hospitals, and is closely linked to a range of general hospitals and community practices across the North West of England.
Notice: This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects", "plans", "will", "estimates", "forecasts", "projects" or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.